In Cohort A [47], 170 patients with ≥ 1 prior systemic treatment for metastatic disease and documented progressive disease (PD) were enrolled, 61.8% being PD-L1-positive by immunohistochemistry (IHC), as defined by a combined positive score (CPS)—a ratio between PD-L1-positive cells (tumor or immune cells) and the total number of tumor cells × 100—being ≥1. This evidence concerns the gene CD274 and neoplasm.